DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.
One wealth manager who pays more than $20,000 a year for membership to a longevity clinic in London was told he had some calcification in the arteries in his neck, as well as an elevated genetic risk ...